v3.25.4
Asset Acquisitions and Collaboration Agreements - Additional Information (Details) - USD ($)
3 Months Ended 12 Months Ended
Jul. 09, 2024
Mar. 31, 2026
Dec. 31, 2025
Dec. 31, 2024
Asset Acquisition [Line Items]        
Total purchase consideration $ 36,200,000      
Cash paid at closing 35,100,000      
Asset acquisition, direct transaction costs $ 1,100,000      
Asset acquisition, contingent consideration, liability     $ 0 $ 0
Gubra Agreement        
Asset Acquisition [Line Items]        
Additional amount eligible to receive upon achievement of certain milestones       53,500,000
Minimum        
Asset Acquisition [Line Items]        
Percentage of royalty obligations on future sales 4.00%      
Maximum        
Asset Acquisition [Line Items]        
Percentage of royalty obligations on future sales 7.00%      
Forecast | Gubra Agreement        
Asset Acquisition [Line Items]        
Milestone payment for development candidate   $ 4,000,000    
Eiger BioPharmaceuticals, Inc.        
Asset Acquisition [Line Items]        
Transaction costs $ 35,100,000      
Acquired in-process research and development expense     $ 0 $ 36,200,000